Elicio Therapeutics, Inc. (ELTX)
| Market Cap | 180.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.90M |
| Shares Out | 13.88M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ELTX
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. For therapies designed to engage the immune system to treat disease, it is critical to target activation at the unique location where adaptive immune responses are generated. Our proprietary Amphiphile, or AMP, platform delivers immunotherapeutics directly to the “brain center” of the immune system - the lymph nodes. We believe this site-specific delivery of disease-specific antigens, adjuv... [Read more]
News
Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines
BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, to...
Elicio Therapeutics Presents Preclinical Data on its Lymph Node-Targeted SARS-CoV-2 Amphiphile Vaccine, ELI-005, at the 2022 Keystone Symposia on Viral Immunity: Basic Mechanisms and Therapeutic Applications
BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, tod...
Elicio Therapeutics Presents Design of Ongoing AMPLIFY-201 Study in Mutant KRAS-Driven Cancers at ASCO Annual Meeting 2022
BOSTON, May 27, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, toda...
Elicio Therapeutics Announces Publication of Preclinical Data Showing AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy Enhances Anti-Tumor Function and Eradicates Solid Tumors
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, tod...
Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo® (cemiplimab) in KRAS-Driven Tumors
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, anno...
Elicio Therapeutics Announces Appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and Promotion of Dr. Peter DeMuth to Chief Scientific Officer
BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, toda...
Elicio Therapeutics Moves into Boston's Seaport District and Provides Update on Programs
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, to...
Elicio Therapeutics Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies at the 2021 Society for Immunotherapy of Cancer Annual Meeting
CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other dis...
Elicio Therapeutics Announces First Patient Dosed in the ELI-002 (AMPLIFY-201) study in KRAS-Driven Cancers
CAMBRIDGE Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other dise...